ZIOPHARM Oncology (NASDAQ:ZIOP) Rating Increased to Hold at Zacks Investment Research

ZIOPHARM Oncology (NASDAQ:ZIOP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Saturday, Zacks.com reports.

According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “

ZIOP has been the subject of a number of other reports. BidaskClub lowered ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, September 25th. HC Wainwright reaffirmed a “buy” rating and issued a $6.50 price target on shares of ZIOPHARM Oncology in a report on Wednesday, October 2nd. ValuEngine lowered ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 2nd. Finally, Raymond James set a $6.50 price target on ZIOPHARM Oncology and gave the stock an “outperform” rating in a report on Wednesday, October 2nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $6.25.

Shares of ZIOPHARM Oncology stock traded up $0.02 during trading hours on Friday, reaching $4.24. The company had a trading volume of 965,984 shares, compared to its average volume of 1,590,404. ZIOPHARM Oncology has a one year low of $1.56 and a one year high of $7.25. The business has a fifty day simple moving average of $4.58 and a 200 day simple moving average of $4.87. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.33 and a quick ratio of 6.33. The firm has a market cap of $681.10 million, a PE ratio of -8.83 and a beta of 2.65.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.09) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.01). During the same period in the previous year, the company earned ($0.12) earnings per share. On average, research analysts forecast that ZIOPHARM Oncology will post -0.36 EPS for the current year.

Several institutional investors have recently bought and sold shares of ZIOP. Aperio Group LLC purchased a new stake in shares of ZIOPHARM Oncology in the second quarter worth $35,000. Niemann Capital Management Inc. purchased a new stake in shares of ZIOPHARM Oncology in the second quarter worth $79,000. Prudential Financial Inc. raised its position in shares of ZIOPHARM Oncology by 18.8% in the second quarter. Prudential Financial Inc. now owns 16,673 shares of the biotechnology company’s stock worth $97,000 after buying an additional 2,640 shares in the last quarter. A.R.T. Advisors LLC purchased a new stake in shares of ZIOPHARM Oncology in the second quarter worth $98,000. Finally, Tower Research Capital LLC TRC raised its position in shares of ZIOPHARM Oncology by 20,325.9% in the second quarter. Tower Research Capital LLC TRC now owns 17,362 shares of the biotechnology company’s stock worth $101,000 after buying an additional 17,277 shares in the last quarter. 43.19% of the stock is owned by hedge funds and other institutional investors.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

Further Reading: How Do Investors Open a Backdoor Roth IRA?

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.